Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
Biocardia Inc(BCDA)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for BCDA
09/25/2026: BCDA (1-star) is a SELL. SELL for 5 days. Simulated Profits (-4.42%). Updated daily EoD!
BioCardia Inc. is a clinical-stage biotechnology company focused on developing proprietary catheter-based delivery systems and regenerative cell therapies for cardiovascular diseases. The company is characterized by its dual-track business model, seeking to control both the delivery platform and the therapeutic agent. Its main strengths lie in its specialized technology and a clear focus on addressing high-unmet-need heart conditions. However, the company faces significant risks, including the absence of commercial revenue, reliance on ongoing clinical trial success, and intense competition from much larger medical conglomerates. This stock is best suited for speculative investors comfortable with high volatility and long-term clinical trial risks who should monitor regulatory milestones closely.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | The company offers potential long-term growth through clinical success but carries significant early-stage risk. |
| Momentum investor | Weak fit | Momentum is often absent unless driven by major clinical catalysts or positive regulatory news. |
| Value investor | Weak fit | Valuation is difficult to determine based on standard metrics as the company lacks commercial revenue. |
| Dividend investor | Weak fit | BioCardia does not pay dividends and reinvests all capital into R&D. |
| Low-risk investor | Weak fit | High volatility and the risk of clinical trial failure make this unsuitable for risk-averse investors. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | Small-cap biotech stocks frequently experience sharp price movements based on news cycles. |
| Valuation risk | High | Speculative valuation makes the stock sensitive to funding needs and clinical outcomes. |
| Competition risk (cardiovascular medical technology) | High | Large incumbents with greater resources may outcompete or render specific technologies obsolete. |
| Business quality | Medium | While the technology is innovative, the company remains in a developmental stage with no commercial revenue. |
| Dividend income | Low / none | There is no income component to this investment. |
| Execution risk | High | Success relies entirely on the execution of complex clinical trials and obtaining regulatory approval. |
Price Behavior
Downtrend
The stock has experienced a sustained decline in price over recent periods.
Choppy
The stock has experienced frequent reversals and pronounced short-term price swings.
Analysis of Past Performance
Type Stock | Historic Profit -69.24% | Avg. Invested days 8 | Today’s Advisory SELL |
Upturn Advisory Rating  | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/25/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 16.20M USD | Price to earnings Ratio - | 1Y Target Price 15.5 |
Price to earnings Ratio - | 1Y Target Price 15.5 | ||
Volume (30-day avg) 316.4K shares | Beta 0.55 | 52 Weeks Range 0.75 - 1.58 | Updated Date 09/25/2026 |
52 Weeks Range 0.75 - 1.58 | Updated Date 09/25/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.6 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Regenerative Therapeutics | Clinical-stage pipeline focusing on CardiAMP and CardiALLO therapies. | The company is an R&D venture currently spending money to prove its medical treatments work. |
| Cardiovascular Devices | Proprietary delivery catheters like the Helix system. | The company develops specialized tools to deliver advanced medicine directly to the heart. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Valuation
Trailing PE - | Forward PE - | Enterprise Value 12.07M | Price to Sales(TTM) 2520.59 |
Enterprise Value 12.07M | Price to Sales(TTM) 2520.59 | ||
Enterprise Value to Revenue 23.81 | Enterprise Value to EBITDA -3.16 | Shares Outstanding 15.14M | Shares Floating 12.26M |
Shares Outstanding 15.14M | Shares Floating 12.26M | ||
Percent Insiders 17.91 | Percent Institutions 14.79 |
Upturn AI Summary
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
About Biocardia Inc
Exchange NASDAQ | Headquarters Sunnyvale, CA, United States | ||
IPO Launch date 2008-03-14 | CEO, President & Director Dr. Peter A. Altman Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 17 | Website https://www.biocardia.com |
Full time employees 17 | Website https://www.biocardia.com | ||
BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. The company's lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia. It also provides CardiALLO, an allogeneic mesenchymal stem cell therapy which is in phase II for ischemic heart failure; allogeneic cell therapy platform; and PulmALLO, an allogeneic mesenchymal stem cell therapy for acute respiratory distress syndrome. In addition, the company offers the Helix biotherapeutic delivery system for minimally invasive targeted delivery of biologic agents to the heart; Heart3D for fusion imaging; and morph DNA and avance steerable introducers. It has a license and distribution agreement with Biomet Biologics, LLC. BioCardia, Inc. is based in Sunnyvale, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.